The Canadian Renin-Angiotensin System medicine market is on a declining trajectory. Sales for 2023 were $18.8 per capita, with a projected drop as low as $13.4 per capita by 2028. The year-on-year decline is consistent, showing -6.21% between 2024 and 2025, -6.02% from 2025 to 2026, -7.05% from 2026 to 2027, and -7.59% from 2027 to 2028. The five-year compound annual growth rate (CAGR) is expected to average -6.79%.

Looking forward, several trends could shape the market:

Increasing competition from generics may exert downward pressure on prices.
Advances in alternative therapies may offer more cost-effective solutions.
Healthcare policy changes could impact medication affordability and accessibility.
Technological advancements could improve drug efficacy, altering demand.

Download as XLS

More about Antihypertensive Industry 2025-2029